NEW YORK and SUNNYVALE, Calif., June
2, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:
VGAC), a special purpose acquisition company sponsored by Virgin
Group ("VGAC" or the "Company"), reminds its shareholders to
vote on the Company's proposed business combination with 23andMe,
Inc. ("23andMe"), a leading consumer genetics and research company,
and the related proposals that will come before VGAC's
extraordinary general meeting of shareholders (the "Special
Meeting"). The VGAC board unanimously recommends that shareholders
vote "FOR" the business combination and the other proposals that
will come before the Special Meeting.
The Special Meeting is scheduled for June
10, 2021 at 10:00 a.m. ET to
approve, among other things, the business combination with 23andMe.
The Special Meeting will be held at the offices of Davis Polk & Wardwell LLP located at 450
Lexington Ave., New York, New York
10017 and virtually via the Internet.
Shareholders of record as of the close of business on
May 5, 2021 are entitled to vote on
matters that come before the Special Meeting. The Company asks that
all shareholders vote their shares regardless of how many shares
they hold.
Shareholders are encouraged to submit their vote as soon as
possible to ensure they are represented at the Special Meeting.
Shareholders can vote their VGAC shares using one of the methods
detailed below. Shareholders needing assistance in voting their
VGAC shares can contact VGAC's proxy solicitor, Morrow Sodali LLC,
by calling (800) 662-5200, or banks and brokers can call collect at
(203) 658-9400, or by emailing
vgac.info@investor.morrowsodali.com.
- Vote Online (Highly Recommended): Follow the
instructions provided by your broker, bank or other nominee on the
Voting Instruction Form ("VIF"). This form was mailed to the
address on record with your broker and also emailed if you elected
electronic notification. You will need your voting control number
which is included on the VIF to vote online at the VGAC meeting
website (www.proxydocs.com/VGAC).
- Vote by Telephone: Follow the instructions provided by
your broker, bank or other nominee on the VIF mailed (or emailed)
to you. You will need your voting control number which is included
on the VIF to vote via automated telephone service.
If shareholders have not received their voting information, they
are encouraged to reach out to their broker, bank or other nominee
and request their control number and voting information so they can
be sure to vote their VGAC shares and be represented at the Special
Meeting.
If the proposals at the Special Meeting are approved, subject to
the satisfaction or waiver (as applicable) of other customary
closing conditions, the closing of the business combination is
currently expected to occur on June 16,
2021. Upon the closing, VGAC will change its name to 23andMe
Holding Co. ("New 23andMe"), and New23andMe Class A common stock
and New23andMe warrants will be listed on The Nasdaq Global Select
Market ("Nasdaq"). Trading is expected to begin on Nasdaq on
June 17, 2021, under the new ticker
symbol "ME" for the New23andMe Class A common stock and "MEUSW" for
the New23andMe warrants.
About 23andMe, Inc.
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics
and research company. Founded in 2006, 23andMe's mission is to help
people access, understand, and benefit from the human genome.
23andMe has pioneered direct access to genetic information as the
only company with multiple Food and Drug Administration
authorizations for genetic health risk reports. 23andMe has created
the world's largest crowdsourced platform for genetic research,
with 80% of its customers electing to participate. The 23andMe
research platform has generated more than 180 publications on the
genetic underpinnings of a wide range of diseases, conditions, and
traits. The platform also powers the 23andMe therapeutics group,
currently pursuing drug discovery programs rooted in human genetics
across a spectrum of disease areas, including oncology,
respiratory, and cardiovascular diseases, in addition to other
therapeutic areas. More information is available at
www.23andMe.com.
About VG Acquisition Corp.
VG Acquisition Corp. was formed for the purpose of effecting a
merger, amalgamation, share exchange, asset acquisition, share
purchase, reorganization, or similar business combination with one
or more businesses. The management team includes: Sir Richard Branson, founder of VGAC, a renowned
global entrepreneur, and founder of the Virgin Group; Josh Bayliss, VGAC's Chief Executive Officer and
director, who is the Chief Executive Officer of the Virgin Group
and is responsible for the Virgin Group's strategic development,
licensing of the brand globally, and management of direct
investments on behalf of the Virgin Group in various companies
around the world; and Evan Lovell,
VGAC's Chief Financial Officer and director, who is the Chief
Investment Officer of the Virgin Group and is responsible for
managing the Virgin Group's investment team and portfolio in
North America. More information is
available at https://vgacquisition.com/.
Forward-Looking Statements
This communication contains certain "forward-looking statements"
including statements regarding the occurrence and anticipated
timing of the Business Combination between VGAC and 23andMe and
regarding the listing of shares of the combined company on Nasdaq.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intends," "may," "might," "plan," "possible,"
"potential," "predict," "project," "should," "would," and similar
expressions may identify forward-looking statements, but the
absence of these words does not mean that a statement is not
forward-looking. The forward-looking statements contained herein
are based on VGAC's current expectations and beliefs concerning
future developments and their potential effects, but there can be
no assurance that these will be as anticipated. These
forward-looking statements involve a number of risks, uncertainties
(some of which are beyond the control of VGAC), or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These factors include, among others:
the inability to complete the Business Combination, including due
to the failure to receive required security holder approvals, or
the failure of other closing conditions. Except as required by law,
VGAC does not undertake any obligation to update or revise any
forward-looking statements whether as a result of new information,
future events, or otherwise.
Additional Information About the Proposed Business
Combination and Where To Find It
VGAC has filed with the Securities and Exchange Commission (the
"SEC") a Registration Statement on Form S-4, as amended (the "Form
S-4"), which included the definitive proxy statement of VGAC, a
prospectus, and 23andMe's consent solicitation statement. The Form
S-4 was declared effective on May 14,
2021. The definitive proxy statement/prospectus and other
proxy materials were mailed to VGAC's shareholders of record as of
the close of business on May 5, 2021.
Shareholders of VGAC and other interested persons are advised to
read the Form S-4, the definitive proxy statement/prospectus
included in the Form S-4, and documents incorporated by reference
therein filed in connection with the proposed Business Combination
because these documents contain important information about VGAC,
23andMe, and the Business Combination. Shareholders will also be
able to obtain copies of the Form S-4 and the proxy
statement/prospectus, without charge, by directing a request to: VG
Acquisition Corp. 65 Bleecker Street, 6th Floor, New York NY 10012. These documents and VGAC's
annual and other reports filed with the SEC can also be obtained,
without charge, at the SEC's internet site
(https://www.sec.gov).
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities, or a solicitation
of any vote or approval, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
Participants in the Solicitation
VGAC, 23andMe, and their respective directors, executive
officers, other members of management, and employees may be deemed
to be participants in the solicitation of proxies from VGAC's
shareholders in connection with the Business Combination.
Information regarding the names and interests in the proposed
Business Combination of VGAC's directors and officers is contained
in VGAC's filings with the SEC. Additional information regarding
the interests of such potential participants in the solicitation
process is included in the Form S-4 (and the definitive proxy
statement/prospectus) and other relevant documents filed with the
SEC.
Contacts
Investor Relations:
23andMe
Sard Verbinnen & Co
23andMe-SVC@sardverb.com
VG Acquisition Corp.
FTI Consulting
US, Canada, South America, Australia – Antonia
Gray / Grace Altman
Antonia.Gray@fticonsulting.com / Grace.Altman@fticonsulting.com
UK, Middle East, Asia, Africa
– Charles Palmer
Charles.Palmer@fticonsulting.com
Media Relations:
23andMe
press@23andMe.com
Sard Verbinnen & Co
Paul Kranhold / John Christiansen / Chris Kittredge 23andMe-SVC@sardverb.com
VG Acquisition Corp.
FTI Consulting
US, Canada, South America, Australia – Antonia
Gray / Grace Altman
Antonia.Gray@fticonsulting.com / Grace.Altman@fticonsulting.com
UK, Middle East, Asia, Africa
– Charles Palmer
Charles.Palmer@fticonsulting.com
View original
content:http://www.prnewswire.com/news-releases/virgin-groups-vg-acquisition-corp-reminds-stockholders-to-vote-on-its-proposed-business-combination-with-23andme-inc-301304475.html
SOURCE VG Acquisition Corp.